The Selective COX-2 Inhibitor Etoricoxib Reduces Acute Inflammatory Markers in a Model of Neurogenic Laryngitis but Loses Its Efficacy With Prolonged Treatment

Inflammation Research - Switzerland
doi 10.1007/s00011-010-0185-5

Related search